Number of pages: 100 | Report Format: PDF | Published date: August 23, 2022
Historical Years – 2020 | Base Year – | Forecasted Years – 2022-2030
The global acute coronary syndrome market was pegged at US$ 30.3 billion in 2021 and is expected to witness a CAGR of 10.5% during the forecast period.
Acute coronary syndrome (ACS) is a set of symptoms caused by a reduction in blood supply to heart muscles, which causes some of the heart muscles to either stop working altogether or to die. The most common symptom is crushing, central chest pain that frequently radiates to the left shoulder or angle of the jaw and is followed by nausea and perspiration. Shortness of breath, soreness or discomfort in one or both arms, nausea, sweating, and other symptoms are possible. Blood tests or an ECG can be utilised to diagnose ACS. Particularly among women, elderly patients, and patients with diabetes mellitus, many people with acute coronary syndromes have symptoms other than chest pain.
The two main reasons driving market expansion are an increase in the number of elderly people and an increase in the prevalence of heart illnesses. However, strict government guidelines for drug approval are anticipated to limit market expansion. During the course of the analysis period, the market is anticipated to experience new development prospects due to improvements in healthcare infrastructure in developing areas like Asia-Pacific and Latin America.
Major companies in interventional cardiology and peripheral vascular devices have created opportunities for commercial expansion in diverse countries through strategic product introductions and partnerships. The corporations are able to expand their market positions thanks to this tactic. Therefore, it is anticipated that strategic initiative will present the market participants with a prime opportunity to accelerate the expansion of their revenue. However, Acute coronary syndrome market expansion is constrained and challenged by the rising expense of therapeutic surgery and the absence of disease management services and support in low-income nations.
The global acute coronary syndrome market has been analyzed from four perspectives by type, drug, end user, and region.
Acute Coronary Syndrome Market by Type
Based on type, the global acute coronary syndrome market has been segmented into vial unstable angina, ST-elevation myocardial infraction (STEMI), non-ST-elevation, and myocardial infraction (NSTEMI). The risk of experiencing unstable angina, which can result in a heart attack, rises when the body is lacking in blood flow and oxygen. The most common cause of NSTEMI is a partial blood clot blockage of the coronary artery. When a clot completely blocks a coronary artery, a STEMI occurs. This condition increases the patient's risk of dying.
Acute Coronary Syndrome Market by Drug
Based on drug, the global acute coronary syndrome market has been segmented into antihypertensive drug, antithrombotic drug, and statins drug. Antihypertensive drugs are predicted to expand profitably over the projection period due to rising rates of hypertension, myocardial infarction, and stroke
Acute Coronary Syndrome Market by End User
Based on end user, the global acute coronary syndrome market has been segmented into hospitals, ambulatory surgical centre, diagnostic centres and others. The hospital segment dominated the market during forecast period due to an increase in the number of hospitals.
Acute Coronary Syndrome Market by Region
Based on the region, the global acute coronary syndrome market has been segmented into North America, Europe, Asia Pacific, and Rest of the World. North America dominated the market during forecast period due to the increasing incidence of coronary heart disease and the presence of a highly established healthcare industry in the area. Additionally, the industry is boosted by rising healthcare costs and the presence of market participants in the region.
The Asia Pacific region has the fastest growing market due to the presence of expanding economies like China, India, Australia, and others in the region. A large patient population, rising healthcare costs, and a fast-growing healthcare sector all contribute to the market's expansion.
Some of the prominent market players of the global acute coronary syndrome include
Rise in prevalence of chronic diseases, such as coronary artery disease, ischemic heart disease, and vascular diseases; growing geriatric population, wide range of products offered by market players are the key factors for the growth of the market.
Some of the prominent market players of the global acute coronary syndrome include Teva Pharmaceuticals, Pfizer Inc., Dr. Reddy’s Laboratories, Boehringer Ingelheim among others.
Antihypertensive drugs are predicted to expand profitably over the projection period.
North American market for acute coronary syndrome dominated the region during forecast period.
Due to significant investments, complex cardiac devices, and escalating prices, the costs would increase. The additional cost would cause patients to receive delayed care in hospitals and clinics, and the approval process for these items is quite demanding and time-consuming.
*Insights on financial performance is subject to availability of information in public domain